Health and Beauty

Dementia Of The Alzheimers Type Diagnostic Criteria

This RSS feed URL is deprecated

Do I have Alzheimer's or don't I?

Do I have Alzheimer's or don't I? Alzheimer's is a complex disease to diagnose. The science is just not there yet. Sixty to 80 percent of dementia cases are said to be due to Alzheimer's. But postmortem tests of elderly patients have found that dementia has several causes. "Up to one

I lived with an Alzheimer's diagnosis for years. But a recent test says I may not have it after all.

I lived with an Alzheimer's diagnosis for years. But a recent test says I may not have it after all. Alzheimer's is a complex disease to diagnose. The science is just not there yet. Sixty to 80 percent of dementia cases are said to be due to Alzheimer's. But postmortem tests of elderly patients have found that dementia has several causes. “Up to one

Do I have Alzheimer's? My journey with a disease that is complex to diagnose

Do I have Alzheimer's? My journey with a disease that is complex to diagnose Alzheimer's is a complex disease to diagnose. The science is just not there yet. Sixty to 80 percent of dementia cases are said to be due to Alzheimer's. But postmortem tests of elderly patients have found that dementia has several causes. “Up to one

Alzheimers Q&A: What are some common easy test assessments for dementia?

Overall, these types of assessments are not diagnostic tests, and these screenings should be given by a health care professional. Poor results on these screenings may indicate probable cognitive impairment. However, more sophisticated testing is

CSF and Brain Markers Highlight Different Facets of Dementia

While biomarkers have opened a window onto Alzheimer’s pathogenesis, the view has remained cloudy. At the Alzheimer’s Association International Conference 2017 held July 16-20 in London, the number of biomarker talks was noteworthy, with nearly one-quarter of all sessions devoted to this topic. So inescapable was the subject that John Hardy of University College London quipped, “This is the biomarkers meeting.” Researchers discussed new data that clarify how various biomarkers relate to each other, and what they say about the underlying disease. Speakers solidified a recent trend showing that cerebrospinal fluid proteins and PET scans, while correlated, provide different types of information, with the former best suited for diagnosis, and the latter better for tracking progression. Several presentations reinforced the idea that tau pathology, rather than amyloid plaques or atrophy, drives cognitive decline, while others discussed how the presence of some of these pathologies can be used to predict others (see Part 2  of this story). Overall, researchers are painting an increasingly panoramic picture of what biomarker data means. Keep an eye on Alzforum for upcoming stories on longitudinal biomarkers and neuroimaging correlates of cognitive reserve.